Category: Diabetes

Introduction and Objective: Small-molecule DYRK1A inhibitors such as harmine stimulate adult human β-cell proliferation; however, only a subset enhances β-cell identity/function. We sought to define the signaling mechanism underlying this phenotype, determine whether it is a class effect or requires DYRK1A inhibition, and identify the responsible pathway in human β-cells.Methods: Primary human islets and R7T1 […]

Introduction and Objective: T2D increases the risk of clinical outcomes in MASH cirrhosis. This post hoc analysis assessed changes in liver disease and insulin sensitivity in participants with baseline T2D and compensated cirrhosis due to MASH in the SYMMETRY trial of efruxifermin.Methods: SYMMETRY (NCT05039450) is a phase 2b, randomized, placebo-controlled trial that evaluated efruxifermin QW […]

Introduction and Objective: Older adults with type 1 diabetes face age-related changes. Dyadic coping, where care partners (CPs) and people with diabetes (PWD) collaboratively manage diabetes, can improve outcomes but is hindered by misaligned illness appraisals (viewing diabetes as individual vs. shared responsibility) and communication difficulties. This study describes experiences of older PWD/CP dyads in […]

Introduction and Objective: HZ has been associated with a higher risk of cardiovascular events, but evidence in T2DM is limited. This analysis assessed associations between HZ and MI/IS in older adults with T2DM.Methods: Using US administrative claims and EHR data (Optum Market Clarity, 2016-2024), adults with T2DM and HZ were identified by ICD-10 diagnosis codes. […]

Introduction and Objective: Type 1 diabetes cell therapies aim to restore normoglycemia by replacing lost beta cells, but low clinical supply and the need for chronic immune suppression are key challenges. CNTY-813 overcomes these challenges via clinical-scale production of Allo-Evasion™ 5.0-engineered iPSC-derived beta islets that are engineered for immune evasion. Thus, CNTY-813 provides an off-the-shelf, […]

Introduction and Objective: We evaluated the effectiveness of CGM versus BGM in the pragmatic management of T2D on insulin in primary care, in a large randomized controlled trial in the upper Midwest.Methods: This two-arm trial was cluster-randomized based on primary care clinic attendance: (BGM 25 clinics) or CGM (25 clinics). We recruited 360 adults with […]

Introduction and Objective: Monitoring of beta cell function in those with preclinical T1D relies on serial frequently sampled oral glucose tolerance tests (OGTT), which poses major challenges given the practical burden and expense of this test. Herein, we validated a fully CGM-derived disposition index (DICGM) – a proxy of beta cell function -computed against the […]

Introduction and Objective: Basal insulin dose titration is traditionally guided by self-monitored FBG and documented hypoglycemic events. This retrospective analysis evaluated CGM-derived indicators for use in dose titration of weekly basal insulin in insulin-naïve adults with T2D.Methods: CGM indicators of FBG were calculated from 3730 weekly insulin dose decisions, while hypoglycemic events were assessed using […]

Introduction and Objective: Despite the widespread digitalization of diabetes care, significant disparities remain in individuals’ skills and confidence using digital health tools. We consulted with patients and clinicians to develop a program, called ADDS (Assistance with Diabetes Digital health Skills), to improve the digital health literacy of adults with type 2 diabetes (T2D) and explored […]

Introduction and Objective: We previously (BMJ Open Diab: e004199, 2024) showed that a 10-day weight-maintaining ketogenic diet in individuals with type 2 diabetes did not change OGTT responses or insulin sensitivity (two-step euglycemic clamp) but increased insulin secretion.To examine the effect of the 10-day weight-maintaining ketogenic or standard diet on fasting plasma glucagon and OGTT […]